What "double" means in capacity terms

Output scales as stations × 2 × rpm. A 37-station double rotary at 80 rpm yields ~355,000 tablets/hour; a 37-station single rotary at the same speed yields ~178,000. The headline sounds like "free doubling," but two rows of stations means two sets of punches and dies, two cam tracks wearing in parallel, and a turret that costs roughly 1.6–1.8× a single rotary of equal station count.

The real cost structure of doubling

• Capital: 1.6–1.8× a comparable single rotary.

• Tooling: punches and dies roughly double — a 37-station double rotary needs 74 upper and 74 lower punches per product.

• Validation: IQ/OQ/PQ covers twice the stations; documentation and FAT time grow, not linearly but meaningfully.

• Floor space & energy: similar footprint to one single rotary, but energy per tablet drops because fixed overhead spreads over more units.

Measured 3-year TCO comparison

At 600 million tablets/year the double rotary beats two singles on labour and energy, but a single rotary at lower volume is cheapest of all. The break-even against two singles lands near 480M tablets/year in this profile.

Compliance burden scales with stations

EU GMP Annex 15, FDA 21 CFR 211, CE (Machinery Directive 2006/42/EC) and ISO 9001 apply regardless, but the validation package for a double rotary must demonstrate uniformity across both station rows — auditors sample from inner and outer rows separately. For drug-device work, ISO 13485 documentation doubles in sample count. Budget the extra qualification week.

Real cases (anonymized)

• EU generic, high-volume: 450M tablets/yr, 45-station double rotary at 70 rpm. Double rotary chosen over two singles specifically to keep one validated line and one operator shift.

• Middle East regional plant: forecast 300M/yr, actual 190M. Bought double rotary; ran at 55% utilisation for two years. A single rotary would have saved ~USD 120,000 in TCO.

• Southeast Asia contract manufacturer: two single rotaries instead of one double, to keep flexibility across different tooling standards for EU vs US clients.

Pain points

• Idling capacity when forecast overshoots reality — capital earning nothing.

• Double tooling spend locked to one product's punch set.

• Longer validation across two station rows slows product changeover.

Misconceptions

• "Double rotary halves my cost per tablet." Only true above break-even volume; below it the fixed cost dominates.

• "Bigger is always safer for growth." Idle capacity is a liability, not a hedge.

• "Two singles equal one double." They differ in labour, footprint and validation strategy.

Machine differences

Procurement pitfalls

• Quoting on forecast volume with no measured 12-month run history.

• Tooling inventory priced for one row only — you need both.

• Omission of the dual-row uniformity test from the OQ protocol.

FAQ

How do I find my break-even?

Model 3-year TCO for single×1, single×2 and double×1 at your real volume; the crossover is typically 450–500M tablets/year.

Is a double rotary faster to validate than two singles?

Often yes for one product family — one line, one operator, one qualification dossier.

Does it use twice the power?

No; similar drive power to a single rotary, so energy per tablet falls.

Can I run two products on one double rotary?

Yes, but each changeover re-validates both station rows — plan tooling swaps carefully.

What tooling standard should I stock?

EU/IPT for Europe/Middle East export, TSM for the US; stock both rows.

Is CE enough for FDA?

No — FDA 21 CFR 211 alignment and a separate validation package are needed for the US.

What lead time should I expect?

14–20 weeks with full tooling and IQ/OQ documentation.

Should a small plant buy double rotary?

Only if measured volume exceeds break-even; otherwise a single rotary or two singles fit better.